TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14999518

Group type: EXPERIMENTAL
Intervention: Antithyroid drug plus intranasal calcitonin (group 2)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Antithyroid drug (group 1)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (group 3)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Antithyroid drug (group 1) and Antithyroid drug plus intranasal calcitonin (group 2)
Number of subjects: 27
Study: 11600827

Group type: EXPERIMENTAL
Intervention: Triple-therapy protocol (zidovudine/lamivudine or stavudine/didanosine or stavudine/lamivudine with protease inhibitor)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Treatment intensification protocol (ritonavir/saquinavir or ritonavir/saquinavir/stavudine)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Induction-maintenance protocol (saquinavir/nelfinavir/lamivudine/stavudine)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Discontinued study medication
Number of subjects: 159
Study: 9647139

Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8034817

Group type: EXPERIMENTAL
Intervention: Support and skill building
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Support, skill building, transfer, and parent training procedures
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Support alone
Number of subjects: 103

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 103

Group type: COMPARATOR
Intervention: Nonstressed controls (26 children from intact homes)
Number of subjects: 103
Study: 3289770

Group type: EXPERIMENTAL
Intervention: Succinylcholine 1.5 mg.kg‐1 after pre‐treatment with d‐tubocurarine 0.05 mg.kg‐1
Number of subjects: 60

Group type: COMPARATOR
Intervention: Atracurium 350 micrograms.kg‐1 after a priming dose of 50 micrograms.kg‐1
Number of subjects: 60
Study: 31867653

Group type: EXPERIMENTAL
Intervention: Cigarettes with <15.8 mg/g nicotine
Number of subjects: 169

Group type: COMPARATOR
Intervention: Higher nicotine doses (2.4, 5.2, and 15.8 mg/g of tobacco)
Number of subjects: 169
Study: 28625852

Group type: EXPERIMENTAL
Intervention: Early discharge intervention with home monitoring by a skilled nurse in neonatal care.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care until discharge (Control group).
Number of subjects: 0
Study: 26116711

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1,800 mg/day for 4 days plus 2,700 mg before the experimental session
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 23411128

Group type: EXPERIMENTAL
Intervention: Cryosupernatant plasma (CSP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Solvent/detergent plasma (SDP)
Number of subjects: 61
Study: 21220730

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 118
Study: 19455501

Group type: COMPARATOR
Intervention: NSAIDs-based prophylaxis for heterotopic ossification (HO)
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Transfusion of red cells or having general as well as epidural or spinal anaesthesia
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Revision surgery
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: Excessive surgical bleeding indicators
Number of subjects: 407
Study: 17576868

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Metoprolol 50 mg
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 14667699

Group type: EXPERIMENTAL
Intervention: Precocious reader
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal comparison 11-year-olds
Number of subjects: 0
Study: 11069188

Group type: EXPERIMENTAL
Intervention: Clinical fractures (hip fractures)
Number of subjects: 6459

Group type: EXPERIMENTAL
Intervention: Clinical fractures (vertebral fractures)
Number of subjects: 6459

Group type: EXPERIMENTAL
Intervention: Clinical fractures (all types)
Number of subjects: 6459

Group type: COMPARATOR
Intervention: Forearm or other fractures (non-hip, non-wrist, nonvertebral)
Number of subjects: 6459
Study: 9049659

Group type: EXPERIMENTAL
Intervention: AM3 treatment
Number of subjects: 3
Study: 8339634

Group type: EXPERIMENTAL
Intervention: BiPAP ventilation for 40 minutes
Number of subjects: 11
Study: 3011891

Group type: EXPERIMENTAL
Intervention: Lacto-ovo-vegetarian (L-O-V) diet
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control omnivore diet
Number of subjects: 59
Study: 28746788

Group type: EXPERIMENTAL
Intervention: Dexamethasone regimen (day 1: intravenous dexamethasone [20 mg] and granisetron [3 mg] before TACE; days 2 and 3: intravenous dexamethasone [8 mg])
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control regimen (day 1: intravenous placebo [saline] and granisetron [3 mg]; days 2 and 3: intravenous placebo)
Number of subjects: 120
Study: 27788510

Group type: EXPERIMENTAL
Intervention: Vitamin C/E supplementation with CCB/amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: ARB/olmesartan or CCB/amlodipine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin C/E supplementation
Number of subjects: 0
Study: 24622120

Group type: EXPERIMENTAL
Intervention: sST2 serial measurement
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Baseline measurement of sST2, GDF-15, and hsTnT
Number of subjects: 151
Study: 24340150

Group type: EXPERIMENTAL
Intervention: Intramedullary free-tissue graft reconstruction
Number of subjects: 6

Group type: COMPARATOR
Intervention: Extramedullary free-tissue graft reconstruction
Number of subjects: 6
Study: 20636654

Group type: EXPERIMENTAL
Intervention: Survey 1 (factual information about harm reduction services)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Survey 2 (no information about harm reduction services, framed heroin use as problematic)
Number of subjects: 260
Study: 19039893

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 404
Study: 16671258

Group type: EXPERIMENTAL
Intervention: Mivacurium (100 microg x Kg(-1))
Number of subjects: 3

Group type: COMPARATOR
Intervention: Succinylcholine (1 mg x Kg(-1)) followed by Mivacurium (100 microg x Kg(-1))
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1 mg x Kg(-1)) preceded by Mivacurium (10 microg x Kg(-1)) and followed by Mivacurium (100 microg x Kg(-1))
Number of subjects: 3
Study: 12858075

Group type: EXPERIMENTAL
Intervention: Plasma exchange therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjunctive therapies (corticosteroids, antiplatelet drugs, immunosuppressive agents)
Number of subjects: 0
Study: 11357697

Group type: EXPERIMENTAL
Intervention: Doubled semitendinosus tendon (SET-group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patellar ligament graft (BTB-group)
Number of subjects: 40
Study: 9183482

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG (LGG)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Oral rehydration solutions (ORS)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Intravenous rehydration
Number of subjects: 123
Study: 8384818

Group type: EXPERIMENTAL
Intervention: Lomefloxacin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 164
Study: 2419292

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CTX) followed by standard treatment (STD RX)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard treatment (STD RX; preoperative irradiation and radical excision or irradiation alone)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (CTX)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard treatment (STD RX)
Number of subjects: 83
Study: 28543751

Group type: EXPERIMENTAL
Intervention: Pilates exercise program with pelvic floor muscle contraction
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (walking and strengthening exercises)
Number of subjects: 50
Study: 27768966

Group type: EXPERIMENTAL
Intervention: 2D ultrasound (n=258)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: 3D ultrasound (n=152)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Overall measurements
Number of subjects: 410
Study: 25421518

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 1146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1146

Group type: EXPERIMENTAL
Intervention: Treatment dropouts (n=185)
Number of subjects: 1146
Study: 22627121

Group type: EXPERIMENTAL
Intervention: Fibrin sealant application (FS+)
Number of subjects: 78

Group type: COMPARATOR
Intervention: No fibrin sealant application (FS-)
Number of subjects: 78
Study: 20127419

Group type: EXPERIMENTAL
Intervention: ICD treatment with ACE medication
Number of subjects: 507

Group type: COMPARATOR
Intervention: ICD treatment without ACE medication
Number of subjects: 507
Study: 19100422

Group type: EXPERIMENTAL
Intervention: calcium, calcitriol, and alendronate
Number of subjects: 46

Group type: COMPARATOR
Intervention: calcium and calcitriol
Number of subjects: 46
Study: 15790985

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 microg twice daily
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 500 microg twice daily
Number of subjects: 1465

Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate combination 50/500 microg twice daily
Number of subjects: 1465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1465
Study: 11551005

Group type: EXPERIMENTAL
Intervention: Solitaire + Solid Bond
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: ALERT + Bond‐1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Surefil + Prime & Bond NT
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Filtek P60 + Single Bond
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: TPH Spectrum + Prime & Bond 2.1
Number of subjects: 16
Study: 9763554

Group type: EXPERIMENTAL
Intervention: ATRA followed by chemotherapy (CT)
Number of subjects: 413
Study: 7828253

Group type: EXPERIMENTAL
Intervention: PCEA with meperidine (Group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural morphine with saline PCEA (Group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural morphine without saline PCEA (Group 3)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural meperidine (Group 1)
Number of subjects: 75
Study: 2969638

Group type: EXPERIMENTAL
Intervention: 100 mg/day of HPR
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 200 mg/day of HPR
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 300 mg/day of HPR
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 1385959

Group type: EXPERIMENTAL
Intervention: Niceritrol 1.5 g daily for 12 weeks (b.i.d.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Niceritrol 1.5 g daily for 12 weeks (t.i.d.)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Niceritrol in patients with initially high Lp(a) (≥20 mg/dl)
Number of subjects: 33
Study: 356507

Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.05 mg/kg body weight)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 28
Study: 31154298

Group type: EXPERIMENTAL
Intervention: Electronic alert containing an AKI-specific order set
Number of subjects: 6030

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6030
Study: 28349233

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 10 mg orally twice daily for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) and Placebo
Number of subjects: 20
Study: 25308290

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Tailored hand exercises
Number of subjects: 490

Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Cost of tailored hand exercise
Number of subjects: 490
Study: 23642329

Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4)
Number of subjects: 546

Group type: COMPARATOR
Intervention: Gemcitabine (1000 mg/m² i.v. weekly for 7 weeks out of 8, then weekly for 3 weeks out of 4) plus placebo
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg every 2 weeks) combined with gemcitabine
Number of subjects: 546

Group type: COMPARATOR
Intervention: Gemcitabine plus placebo
Number of subjects: 546

Group type: EXPERIMENTAL
Intervention: Aflibercept (4 mg/kg every 2 weeks)
Number of subjects: 546
Study: 21644984

Group type: EXPERIMENTAL
Intervention: Full CBT (12 sessions)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Brief CBT (5 sessions with therapist-guided workbooks)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Wait-list group
Number of subjects: 96
Study: 19661781

Group type: EXPERIMENTAL
Intervention: Neoadjuvant radiotherapy
Number of subjects: 1227

Group type: EXPERIMENTAL
Intervention: Node negative patients with 7 or less lymph nodes examined
Number of subjects: 1227
Study: 17503976

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 100 mg/day
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 200 mg/day
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 400 mg/day
Number of subjects: 461

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 461
Study: 15204513

Group type: EXPERIMENTAL
Intervention: Qigong (treatment group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 36
Study: 11182866

Group type: EXPERIMENTAL
Intervention: 12-Step focused group treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Individualized relapse prevention continuing care
Number of subjects: 132
Study: 9644283

Group type: EXPERIMENTAL
Intervention: High levels of advance information
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Moderate levels of advance information
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Absence of advance information
Number of subjects: 26
Study: 8162480

Group type: EXPERIMENTAL
Intervention: Spa therapy for chronic low back pain (3-week therapy programme)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ambulatory care for chronic low back pain
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Spa therapy for chronic low back pain (9 months follow-up)
Number of subjects: 102
Study: 3227043

Group type: EXPERIMENTAL
Intervention: Naloxone 210 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine 15-30 mg
Number of subjects: 0
Study: 31120541

Group type: EXPERIMENTAL
Intervention: Oligofructans from Ophiopogon japonicus
Number of subjects: 234

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study: 28262186

Group type: EXPERIMENTAL
Intervention: Urine methanol concentration on hangover days
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Urine methanol concentration in hangover group
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Urine methanol concentration in hangover-immune group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Urine methanol concentration in hangover group vs hangover-immune group
Number of subjects: 36
Study: 26791800

Group type: EXPERIMENTAL
Intervention: Triple antiemetic therapy with aprepitant, palonosetron, and dexamethasone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Double antiemetic therapy with palonosetron and dexamethasone
Number of subjects: 80
Study: 23816610

Group type: EXPERIMENTAL
Intervention: Aspirin plus extended-release dipyridamole (ASA + ERDP)
Number of subjects: 14676

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 14676
Study: 20581703

Group type: EXPERIMENTAL
Intervention: Traditional (TD) strength training
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Weekly undulating (WUD) strength training
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (C) group
Number of subjects: 42
Study: 18084048

Group type: EXPERIMENTAL
Intervention: r‐hLH (Luveris, 300 IU/day) for 7 days
Number of subjects: 146

Group type: COMPARATOR
Intervention: No r‐hLH treatment
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 16938136

Group type: EXPERIMENTAL
Intervention: Saphora‐Psy questionnaire
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Perceptions of Care questionnaire
Number of subjects: 728

Group type: EXPERIMENTAL
Intervention: Picker Institute questionnaire
Number of subjects: 728
Study: 14618034

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 200

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Sinus rhythm
Number of subjects: 200
Study: 11693741

Group type: EXPERIMENTAL
Intervention: Preconditioning (5 min ischemia/5 min reoxygenation before 90 min ischemia/120 min reoxygenation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Diazoxide (Mito KATP opener, 0.1 mm for 10 min before 90 min ischemia/120 min reoxygenation)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Glibenclamide (10 microm for 10 min exposure prior to PC in diabetic patient groups)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Ischemia alone (90 min ischemia followed by 120 min reoxygenation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Aerobic control (incubated in oxygenated buffer for 210 min)
Number of subjects: 42
Study: 15321242

Group type: EXPERIMENTAL
Intervention: 0.5 % bupivacaine plus 50 microg fentanyl
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.5 % bupivacaine
Number of subjects: 24
Study: 7868662

Group type: EXPERIMENTAL
Intervention: ICI 182,780, 12 mg daily for 7 days
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (11 normal women)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: ICI 182,780 treatment group
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study: 3044182

Group type: COMPARATOR
Intervention: 0.3 mg/kg diltiazem before induction of anesthesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.014 mg diltiazem/kg per min over 20 min before cannulation
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.014 mg diltiazem/kg per min during ECC
Number of subjects: 60
Study: 31475385

Group type: EXPERIMENTAL
Intervention: Approach proposed by VanderWeele et al (2014) for decomposing total causal effect under three scenarios.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extended approach to multiple mediators influenced by exposure-induced mediator-outcome confounder.
Number of subjects: 0
Study: 27770483

Group type: EXPERIMENTAL
Intervention: Immediate birth
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 1835
Study: 25487069

Group type: EXPERIMENTAL
Intervention: Physicians' attitudes toward patients with schizophrenia with bizarre affect (SBA)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Clinical management decisions
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Qualitative data on trust and engagement
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Colleague alerts about SBA
Number of subjects: 256
Study: 23755765

Group type: EXPERIMENTAL
Intervention: Levico and Vetriolo arsenical-ferruginous water
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 21330912

Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine
Number of subjects: 1890

Group type: COMPARATOR
Intervention: Single-dose nevirapine
Number of subjects: 1890

Group type: EXPERIMENTAL
Intervention: Extended-dose nevirapine (for mothers with CD4 > 350 cells/μl)
Number of subjects: 1890
Study: 19826272

Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg/kg/d, max 1.98 mg/kg/d in six divided doses)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 79
Study: 16400058

Group type: EXPERIMENTAL
Intervention: 400 mg I (as oral iodized oil)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 15249521

Group type: EXPERIMENTAL
Intervention: Risk communication training
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: SDM training
Number of subjects: 747

Group type: EXPERIMENTAL
Intervention: Research clinics (more time for consultations)
Number of subjects: 747
Study: 11417301

Group type: EXPERIMENTAL
Intervention: Anti-endothelial cell antibody (AECA) titer measurement in renal transplant recipients with acute rejection (n = 27)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Anti-endothelial cell antibody (AECA) titer measurement post-rejection therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Comparison of AECA titers in hemodialysis patients vs. healthy controls
Number of subjects: 58

Group type: COMPARATOR
Intervention: AECA titer measurement in transplant recipients by dialysis mode
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: AECA titer measurement pre- and post-renal transplantation
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: AECA titer in recipients with acute rejection
Number of subjects: 58
Study: 9180323

Group type: EXPERIMENTAL
Intervention: Intramedullary nailing (group B)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cast immobilisation (group A)
Number of subjects: 39
Study: 1288238

Group type: EXPERIMENTAL
Intervention: UFT (400 mg per day for 6 months)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control group (intravesical chemoprophylaxis only)
Number of subjects: 389
Study: 3834100

Group type: EXPERIMENTAL
Intervention: Program model considering clinical decision making based on patient characteristics, intensity of care, and treatment modalities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Inpatient model
Number of subjects: 0

Group type: COMPARATOR
Intervention: Outpatient model
Number of subjects: 0
Study: 30496529

Group type: EXPERIMENTAL
Intervention: Endometrial scratch (ES)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Non-endometrial scratch (non-ES)
Number of subjects: 191
Study: 30515482

Group type: EXPERIMENTAL
Intervention: Immediate loading group (IL)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Delayed loading group (DL)
Number of subjects: 20